ObsEva files uterine fibroid drug in US, chasing AbbVie, MyovantSwiss biopharma company ObsEva has filed its oral GnRH antagonist linzagolix for the treatment of uterine fibroids in Share XObsEva files uterine fibroid drug in US, chasing AbbVie, Myovanthttps://pharmaphorum.com/news/obseva-filed-uterine-fibroid-drug-in-us-chasing-abbvie-myovant/
Chord gets $16m to challenge Alexion with oral NMOSD drugSwiss biotech Chord Therapeutics has come out of stealth mode with a $16 million first-round financing that will Share XChord gets $16m to challenge Alexion with oral NMOSD drughttps://pharmaphorum.com/news/chord-gets-16m-to-challenge-alexion-with-oral-nmosd-drug/
British biotechs look to Switzerland for clues to post-Brexit successTheresa May yesterday signed the letter that will formally begin the UK’s departure from the European Union, starting Share XBritish biotechs look to Switzerland for clues to post-Brexit successhttps://pharmaphorum.com/transversal-categories/uk-and-europe/british-biotechs-look-switzerland-clues-post-brexit-success/
Anthill extends its presence in DACH regionAnthill, a digital communications agency focused on the life science industry, is expanding its services for local clients Share XAnthill extends its presence in DACH regionhttps://pharmaphorum.com/partner-content-digital/anthill-extends-its-presence-in-dach-region/
A history of NovartisNovartis is one of the world’s top pharmaceutical companies, and along with neighbours Roche, the mainstay of Switzerland’s Share XA history of Novartishttps://pharmaphorum.com/articles/a-history-of-novartis/
